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Abstract
Despite the considerable progress in understanding the molecular bases of acute myeloid leukemia (AML), new
tools to link disease biology to the unpredictable patient clinical course are still needed. Herein, high-throughput
metabolomics, combined with the other “-omics” disciplines, holds promise in identifying disease-specific and
clinically relevant features.
In this study, we took advantage of nuclear magnetic resonance (NMR) to trace AML-associated metabolic trajectory
employing two complementary strategies. On the one hand, we performed a prospective observational clinical trial
to identify metabolic changes associated with blast clearance during the first two cycles of intensive chemotherapy
in nine adult patients. On the other hand, to reduce the intrinsic variability associated with human samples and
AML genetic heterogeneity, we analyzed the metabolic changes in the plasma of immunocompromised mice upon
engraftment of primary human AML blasts.
Combining the two longitudinal approaches, we narrowed our screen to seven common metabolites, for which we
observed a mirror-like trajectory in mice and humans, tracing AML progression and remission, respectively. We
interpreted this set of metabolites as a dynamic fingerprint of AML evolution.
Overall, these NMR-based metabolomic data, to be consolidated in larger cohorts and integrated in more
comprehensive system biology approaches, hold promise for providing valuable and non-redundant information
on the systemic effects of leukemia.
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Re-programming energy metabolism is a hallmark of
cancer [1]. Acute myeloid leukemia (AML) permits
analysis of the impact of a systemic cancer on the me-
tabolism over time. Oncometabolites have been demon-
strated in 5–20 % of AML-harboring mutations in
Isocitrate Dehydrogenase (IDH) genes [2, 3], and the
metabolic profile of AML cell lines can be employed to
investigate drug treatments [4, 5]. Moreover, previous
studies linked AML with perturbation of metabolic path-
ways including glucose metabolism [6, 7]. Nuclear mag-
netic resonance (NMR) is a rapid, highly reproducible
cost-effective analytical tool to profile metabolic fluctua-
tions, requiring minimal sample manipulation and well
suited for automation and high-throughput purposes, thus
ideal for untargeted analysis in clinical applications [8–11].
To study the metabolic changes associated with AML in
patients, we enrolled nine newly diagnosed patients in a
prospective trial (METAM-02 trial, Additional file 1) and
monitored the metabolic trajectory of blast clearance
during the first two cycles of intensive chemotherapy (CT)
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Fig. 1 Metabolic changes in AML patients undergoing intensive chemotherapy. a Patient characteristics. CR1 first complete remission. *UPN#1
developed a lethal fungal pneumonia while in remission after the first consolidation CT cycle. **UPN#3 underwent allogeneic hematopoietic stem
cell transplantation in CR1 and subsequently relapsed. b Outline of the study design. c Superposition of representative 1H Carr-Purcell-Meiboom-
Gill (CPMG) spectra of BM at tp1H (black line) and tp9H (red line) acquired at 37 °C on a Bruker Avance 600-MHz spectrometer. The
1H CPMG NMR
experiment is based on a pulse sequence that strongly reduces the NMR signals deriving from large molecules; herewith, molecules with high molecular
weight are essentially invisible in the 1H spectrum, thus facilitating spectra interpretation and small molecule identification in the presence of large proteins
and lipoproteins. Peaks correspond to the different metabolites: 1—high-, low-, and very low-density lipoproteins (HDL, LDL, VLDL) CH3; 2—isoleucine;
3—leucine; 4—valine; 5—3-aminoisobutyrate; 6—3-hydroxybutyrate; 7—LDL/VLDL CH2; 8—lactate; 9—alanine; 10—lipids CH2CH2CO; 11—acetate;
12—lipids CH2C=C; 13—N-acetyl-glycoproteins (NAG) NHCOCH3; 14—glutamine; 15—lipids CH2CO; 16—acetoacetate; 17—citrate; 18—lipids
C=CCH2C=C; 19—creatinine; 20—creatine; 21—creatine phosphate; 22—glucose; 23—glycerol of lipids CHOCOR; 24—α glucose; 25—poly-unsaturated
fatty acids (UFA); 26—tyrosine; 27—phenylalanine; 28—histidine; 29—formate. d OPLS-DA score plot for pooled PB and BM samples collected
at diagnosis and typing positive (blue circles; n = 6) or negative (green circles; n = 12) for missense mutations in the IDH1/2 genes. OPLS-DA with
N = 18, CV ANOVA p = 0.059, R2 = 0.93, and Q2 = 0.615. The area under the curve (AUC) of the ROC analysis was 0.86 (p < 0.001). e Metabolites
discriminating AML patients with or without IDH gene mutations. Loadings indicate how much the variables, i.e., the metabolites, contribute
to the model. Shown are loadings with jack-knifed confidence interval. The metabolites significantly contributing to the model were selected
based on variable importance in projection >1 and jack-knifed confidence interval of loadings not crossing the zero line. Positive loading values (blue bars)
indicate the metabolites increased in patients with mutated IDH, while negative values (green bars) are associated with increased levels in patients with
wild-type IDH. Note that the concentration levels of the classical IDH mutation oncometabolite (R)-2-hydroxyglutarate were below the NMR detection
limit and that because of the overlap of the resonances associated to CH2 groups of high-, low- and very low-density lipoproteins (HDL, LDL, VLDL) and
the CH2C=C groups of different lipid molecules it was not possible to establish their specific contribution to the model. f OPLS-DA score plot for pooled
PB and BM samples of patients at diagnosis (tp1H, blue circles; n= 18) vs remission after chemotherapy (pooling samples after induction, tp5H, and after
first consolidation, tp9H, green circles; n= 29). OPLS-DA model with N = 47, CV-ANOVA p= 0.006, R
2 = 0.99, and Q2 = 0.671. The AUC of the ROC analysis
was 0.73 (p< 0.001). g Metabolites discriminating AML patients at diagnosis and in remission after chemotherapy. Positive loading values (blue bars)
indicate the metabolites increased in AML patients at tp1H, while negative values (green bars) are associated with increased metabolite levels at tp5H + tp9H
Fig. 2 Metabolic profile of the AML mouse-human model. a Design of the study. b Leukemic cell count (human CD33+, CD45+ values) over time.
c OPLS-DA score plot for healthy mice (tp1M and tp2M; green circles; n = 12) vs mice at tp5M and tp6M (blue circles; n = 12) showing an AML
metabolic signature at an early stage of AML. OPLS-DA model with N = 24, CV-ANOVA p = 0.002, R2 = 0.99, and Q2 = 0.819. The area under the
curve (AUC) of the ROC analysis was 0.96 (p < 0.001). d Metabolites discriminating healthy and human AML-engrafted mice. Positive loading values
(blue bars) indicate the metabolites increased in AML mice, while negative values (green bars) are associated with increased levels in healthy mice
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(Fig. 1a). Peripheral blood (PB), bone marrow (BM), and
urine samples were collected prior, during, and after in-
duction and consolidation CT, resulting in nine time
points (tpH) (Fig. 1b). At the final time point (tp9H), all
patients had achieved complete remission.
Seventy-four PB, 33 BM, and 75 urine samples were
analyzed by NMR spectroscopy (Fig. 1c and Additional
file 1). First, based on results from unsupervised statis-
tical inspection, we decided to pool BM samples with
the respective PB and observed that despite the small
number of cases, supervised orthogonal partial least
squares-discriminant analysis (OPLS-DA) allowed clus-
tering of the samples at diagnosis (tp1H) according to
the presence or absence of mutations in IDH genes
(Fig. 1d, e), supporting the notion that these mutations
have an overall impact on the metabolome [2, 3]. More-
over, OPLS-DA discriminated the metabolic differences
between patients at disease diagnosis and those in remis-
sion (tp5H and tp9H), highlighting 30 metabolites signifi-
cantly contributing to the model (Fig. 1f, g).
To pinpoint the most relevant ones for AML biology,
we integrated our study with a mouse-human AML
model, allowing us to follow the metabolic changes asso-
ciated with disease progression. Six littermate NOD/
SCID γ-chain-null (NSG) mice were infused with 2 × 106
primary AML blasts (from patient #3). PB samples were
collected over time from the same animals before and
after AML infusion for a total of nine time points (tpM)
(Fig. 2a). AML became detectable (blast count > 1 cell/
μl) in the PB at tp5M for all infused mice; thereafter, an
exponential growth started (Fig. 2b). We thus compared
samples before AML infusion (tp1M and tp2M) and in
the exponential phase of disease (tp5M and tp6M).
Possibly due to the lower number of variables present in
the mouse model, OPLS-DA (Fig. 2c) pinpointed only
22 metabolites accounting for AML progression, mainly
involved in pathways related to energy and fatty acid
metabolism (Fig. 2d). The increased lactate level in the
plasma is a typical hallmark of cancer, characterized by
an aerobic glycolytic shift (“Warburg effect”) [1, 12].
Lower plasma levels of cholesterol, lipids, and unsatur-
ated fatty acids were found in AML mice than in healthy
controls, in agreement with previous reports [6, 13, 14],
highlighting an involvement of fatty acid metabolisms in
Fig. 3 Heat maps of human or mouse plasma tracing the trajectory of the seven metabolites associated with AML evolution in both the patients
and mice. a Heat maps of human BM and PB tracing the trajectory of the seven metabolites (averaged normalized metabolite area) associated
with AML evolution in both the mice and patients. b Heat map of mouse PB depicting the trajectory of the seven metabolites (averaged
normalized metabolite area of the six mice) associated with AML evolution in both the mice and patients. Note that leucine, valine, alanine,
citrate, and acetoacetate increased upon AML progression until tp8M and then decreased at tp9M. This reverse effect supported our hypothesis
about a metabolic change due to overall systemic failure at a late stage of disease and not to a specific effect of AML
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AML, possibly related to the demand for lipids and chol-
esterol in tumor proliferation. Also, the increase of
glutamine in AML mice is consistent with cancer since
glutamine is a major carbon and nitrogen source for
tumor cell proliferation [15].
Combining the two longitudinal approaches to trace
AML in patients and mice, we narrowed our screen to
seven metabolites representative of AML tumor burden:
leucine, valine, alanine, glutamine, citrate, acetoacetate,
and lipids CH2CO. We interpreted this set of metabo-
lites as a dynamic fingerprint of AML evolution that
could be followed in a mirror-like trajectory in both
studies (Fig. 3).
Collectively, our results highlight how NMR-based
metabolomics might provide valuable and non-redundant
information on the systemic effects of leukemia, to be
consolidated in larger cohorts, and integrated in more
comprehensive system biology approaches. Although the
limited number of cases investigated in this study
does not allow a meaningful comparison to previous
reports [6, 7], the technical robustness and reproduci-
bility of NMR, together with the minimal sample ma-
nipulations and invasiveness of this technique, appear
well suited to perform longitudinal studies in clinical set-
tings. Moreover, we first provide experimental evidence
on how patient-derived xenografts can be integrated into
metabolomic studies, complementing and narrowing the
screening of clinically relevant metabolites.
Additional file
Additional file 1: Supplementary Methods, Results and Figures. (PDF 966 kb)
Acknowledgements
The authors would like to thank Stefania Trinca and all the San Raffaele URC-
SCP (Clinical Research Office) staff. Laurette Tavel was supported by a fellowship
from Fondazione Veronesi, Giacomo Oliveira was supported by a fellowship
from Fondazione Matterelli sponsored by the Associazione Italiana Leucemie.
Funding
This work was supported by a generous donation from the Comitato Ricerca
Contro la Leucemia (CRCL) and by grants provided from the Italian Ministry
of Health (RF-2011-02351998, RF-2013-02354880 and TRANSCAN HLALOSS),
by the Associazione Italiana per la Ricerca sul Cancro (Start-Up Grant #14162
and Investigator Grant#17468), by the Conquer Cancer Foundation (2014
Young Investigator Award), and by the DKMS Mechtild Harf Foundation.
Availability of data and materials
Not applicable. All data and materials supporting the conclusions of this
article are included within the article.
Authors’ contributions
MGC, FC, LV, and GM designed the study. LT, GQ, FN, and GM performed
and analyzed the NMR experiments. GO and LV designed, performed, and
analyzed the mouse experiments. MGC, AF, FC, and MB contributed to the
patient clinical care and data collection. CT supervised the sample collection
and banking. AA supervised statistical analyses. MGC, LT, GO, FC, LV, and GM
wrote the manuscript. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The METAM02 prospective clinical trial has been approved by the San
Raffaele Ethic Committee, and all patients signed informed consent upon
enrollment. All animal experiments were performed upon approval from the
San Raffaele Institutional Animal Care and Use Committee (IACUC).
Author details
1Unit of Hematology and Bone Marrow Transplantation, IRCCS San Raffaele
Scientific Institute, Via Olgettina 60, 20132 Milan, Italy. 2Biomolecular Nuclear
Magnetic Resonance Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
3Unit of Immunogenetics, Leukemia Genomics and Immunobiology, IRCCS
San Raffaele Scientific Institute, Milan, Italy. 4Molecular Hematology
Laboratory, IRCCS San Raffaele Scientific Institute, Milan, Italy. 5Center for
Statistics in Biomedical Sciences, University Vita-Salute San Raffaele, Milan,
Italy. 6University Vita-Salute San Raffaele, Milan, Italy.
Received: 26 August 2016 Accepted: 18 October 2016
References
1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell.
2011;144:646–74.
2. Losman JA, Looper RE, Koivunen P, Lee S, Schneider RK, McMahon C, et al.
(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its
effects are reversible. Science. 2013;339:1621–5.
3. McKenney AS, Levine RL. Isocitrate dehydrogenase mutations in leukemia.
J Clin Invest. 2013;123:3672–7.
4. Tiziani S, Lodi A, Khanim FL, Viant MR, Bunce CM, Gunther UL. Metabolomic
profiling of drug responses in acute myeloid leukaemia cell lines. PLoS One.
2009;4:e4251.
5. Lodi A, Tiziani S, Khanim FL, Drayson MT, Gunther UL, Bunce CM, et al. Hypoxia
triggers major metabolic changes in AML cells without altering indomethacin-
induced TCA cycle deregulation. ACS Chem Biol. 2011;6:169–75.
6. Wang Y, Zhang L, Chen WL, Wang JH, Li N, Li JM, et al. Rapid diagnosis and
prognosis of de novo acute myeloid leukemia by serum metabonomic
analysis. J Proteome Res. 2013;12:4393–401.
7. Chen WL, Wang JH, Zhao AH, Xu X, Wang YH, Chen TL, et al. A distinct
glucose metabolism signature of acute myeloid leukemia with prognostic
value. Blood. 2014;124:1645–54.
8. Emwas AH, Luchinat C, Turano P, Tenori L, Roy R, Salek RM, et al.
Standardizing the experimental conditions for using urine in NMR-based
metabolomic studies with a particular focus on diagnostic studies: a review.
Metabolomics. 2015;11:872–94.
9. Nagana Gowda GA, Raftery D. Can NMR solve some significant challenges
in metabolomics? J Magn Reson. 2015;260:144–60.
10. Alonso A, Marsal S, Julia A. Analytical methods in untargeted metabolomics:
state of the art in 2015. Front Bioeng Biotechnol. 2015;3:23.
11. Nicholson JK, Holmes E, Kinross JM, Darzi AW, Takats Z, Lindon JC.
Metabolic phenotyping in clinical and surgical environments. Nature. 2012;
491:384–92.
12. Warburg O. On the origin of cancer cells. Science. 1956;123:309–14.
13. Tiziani S, Kang Y, Harjanto R, Axelrod J, Piermarocchi C, Roberts W, et al.
Metabolomics of the tumor microenvironment in pediatric acute
lymphoblastic leukemia. PLoS One. 2013;8:e82859.
14. Beloribi-Djefaflia S, Vasseur S, Guillaumond F. Lipid metabolic
reprogramming in cancer cells. Oncogenesis. 2016;5:e189.
15. Souba WW. Glutamine and cancer. Ann Surg. 1993;218:715–28.
Carrabba et al. Journal of Hematology & Oncology  (2016) 9:115 Page 5 of 5
